化合物 Fedratinib|T1995

Fedratinib
936091-26-8

￥265 2mg 起订

￥379 5mg 起订

￥543 10mg 起订

上海更新日期：2024-09-14

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 化合物 Fedratinib

英文名称：: Fedratinib

CAS号：: 936091-26-8

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.96%

产品类别：: 抑制剂

货号：: T1995

Product Introduction

Bioactivity

名称	Fedratinib
描述	Fedratinib (TG-101348) is a JAK2 inhibitor that is selective, ATP-competitive, and orally active, inhibiting JAK2 and JAK2V617F kinases (IC50=3 nM). Fedratinib induces apoptosis in tumor cells and may be used in myeloproliferative diseases.
细胞实验	Cells were treated with DMSO and increasing concentrations of inhibitor for 4 hr in RPMI-1640 before collected in 13 Cell Lysis Buffer, containing 1 mM PMSF, and protease inhibitor cocktail tablets. Protein lysates were quantified with BCA assay. Similar protein amounts were mixed with Laemmli sample buffer plus b-mercaptoethanol, boiled for 5 min, and separated on a 4%–15% Tris-HCl gradient electrophoresis gel. Gels were blotted onto a 0.45 mm nitrocellulose membrane, which was blocked in 5% nonfat dry milk and incubated with primary antibodies in either blocking solution or 5% BSA. The membranes were subsequently incubated with a mixture of donkey anti-rabbit IgG conjugated with infrared fluorophore (700 nm emission) and goat anti-mouse IgG conjugated with infrared fluorophore (800 nm emission). Following washing with PBS, the membranes were scanned on an Odyssey scanner to detect total (red) and phospho-STAT5 (green) proteins [1].
激酶实验	IC50 values for TG101348 are determined commercially using the InVitrogen kinase profiling service for a 223 kinase screen that included JAK2 and JAK2V617F or Carna Biosciences for the screen of all Janus kinase family members including JAK1 and Tyk2. ATP concentration is set to approximately the Km value for each kinase [1].
动物实验	The murine BM transplant model was generated and analyzed exactly as previously described. Briefly, C57BL/6 mice were intravenously injected with 1×10^6 whole bone marrow expressing JAK2V617F. Full development of disease was assessed with differential peripheral blood counts at day 26 after bone marrow transplantation. TG101348 was administered by oral gavage twice daily (b.i.d.) at 60 mg/kg, 120 mg/kg, or placebo from day 28 on for 42 days. Differential blood counts were assessed by retro-orbital nonlethal eye bleeds using EDTA glass capillary tubes before study initiation, during the study, and at study endpoints. C57/Bl6 mice were sacrificed at study endpoint or at times indicated based on an IUCAC-approved protocol that includes assessment of morbidity by > 10% loss of weight, scruffy appearance, lethargy, and/or splenomegaly extending across the midline. For histopathology, tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin or, to assess for fibrosis, stained with reticulin. Images of histological slides were obtained on a Nikon Eclipse E400 microscope equipped with a SPOT RT color digital camera model 2.1.1. Images were analyzed in Adobe Photoshop 6.0. For flow cytometry, cells were washed in PBS, washed in 2% fetal bovine serum, blocked with Fc-Block for 10 min on ice, and stained with monoclonal antibodies in PBS and 2% FCS for 30 min on ice. Antibodies used were allophycocyanin (APC)-conjugated ter119, Gr-1, CD4, and B220 and phycoerythrin (PE)-conjugated, Mac1, CD8 (all 1:200), and CD71(1:100) rat anti-mouse. After washing, cells were resuspended in PBS and 2% FCS containing 0.5 mg/ml 7-amino-actinomycin D (7-AAD) to allow discrimination of nonviable cells. Flow cytometry was performed on a FACS Calibur cytometer, at least 10,000 events were acquired, and data were analyzed using FloJo software.The results are presented as graphs and representative dot plots of viable cells selected on the basis of scatter and 7-AAD staining [1].
体外活性	方法：人成红细胞白血病细胞 HEL 和 Ba/F3 JAK2V617F 细胞用 Fedratinib (0-30 µM) 处理 72 h，使用 XTT assay 检测细胞增殖。结果：Fedratinib 抑制了携带 JAK2V617F 突变的 HEL 细胞系以及表达人 JAK2V617F (Ba/F3 JAK2V617F) 的鼠前 B 细胞系的增殖，两种细胞系的 IC50 值分别为 305 nM 和 270 nM。[1] 方法：人骨髓间充质干细胞 hMSC-TERT 用 Fedratinib (3 µM) 处理 10 天，进行碱性磷酸酶 (ALP) 染色检测成骨分化。结果：Fedratinib 处理的 hMSC-TERT 细胞表现出 ALP 产生的显著减少。与对照细胞相比，成骨细胞分化诱导后第 10 天的 ALP 活性测量值降低。Fedratinib 对 hMSC-TERT 细胞的活力没有产生显著影响。[2]
体内活性	方法：为研究对已建立的真性红细胞增多症的疗效，将 Fedratinib (60-120 mg/kg) 灌胃给药给 C57BL/6 小鼠骨髓移植模型，每天两次，持续 42 天。结果：在接受治疗的动物中，红细胞压积和白细胞计数在统计学上显著降低，髓外造血的减少/消除呈剂量依赖性，至少在某些情况下，有证据表明骨髓纤维化减轻。[1]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	10% DMSO+40% PEG300+5% Tween 80+45% Saline : 9.3 mg/mL (17.73 mM), Working solution is recommended to be prepared and used immediately. DMSO : 50 mg/mL (95.3 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字	Apoptosis \| Fedratinib \| STAT5 \| Inhibitor \| Janus kinase \| phosphorylation \| FLT3 \| myeloproliferative \| SAR-302503 \| JAK2V617F \| orally \| inhibit \| SAR302503 \| anti-proliferation \| JAK2 \| TG 101348 \| TG101348 \| JAK \| RET \| anti-cancer
相关产品	Lidocaine hydrochloride \| Metronidazole \| 5-Fluorouracil \| Stavudine \| Tributyrin \| Dextran sulfate sodium salt (MW 4500-5500) \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Sodium 4-phenylbutyrate \| Kaempferol
相关库	抑制剂库 \| 经典已知活性库 \| 已知活性化合物库 \| EMA 上市药物库 \| 激酶抑制剂库 \| FDA 上市药物库 \| 药物功能重定位化合物库 \| FDA 上市激酶抑制剂库 \| 抗癌临床化合物库 \| 抗癌药物库

TG-101348|||SAR 302503|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子